Online Congress

12TH International Congress on Spondyloarthritides

9 - 11 September 2021

PROGRAMME
Dear colleagues and friends,

Unprecedented times... required unprecedented measures. Due to the worldwide pandemic, we were not be able to invite you all to the Twelfth International Congress on Spondyloarthritides in 2020, but will try to make it up now in September 2021.

The Belgian COVID-19 measures and internal rules of the University of Gent, allow us to welcome only a small number of participants to Gent. We therefore were forced to restrict the live congress to the Organising and Scientific Committees, the speakers and the sponsors, without whose support the organisation of this congress would not be possible.

However, we are pleased to welcome you to our online platform where you and many international colleagues can tune in and view the talks in real-time or at a convenient time for a month after the congress dates. Furthermore, the platform offers ample opportunity for networking.

The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters. To facilitate the organisation of a live event, the local and scientific organizers focused on excellent speakers from continental Western Europe. We have not forgotten our far-away friends and colleagues and hope to see you back in 2022 at the next full edition.

The programme for the 2021 congress still offers a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics.

In 2018, the ‘Gent Oration’ was introduced, aimed to honor a scientist or clinician with an established trajectory in the field which we expect with time, to become one of the main highlights of the congress. It is our great pleasure to welcome Professor Maxime Dougados as the inaugural Gent orator in this second edition.

We look forward to meeting you online at the Twelfth International Congress on Spondyloarthritides and remain,

Yours sincerely,

Rik Lories, President
Dirk Elewaut and Filip Van den Bosch, Local Organisers
Thursday 9 September

12.50 Welcome Address
Rik Lories, Congress President

SESSION 1: Pain, the next frontier in spondyloarthritis
Chairs: Kurt De Vlam & Lianne Gensler

13.00 INV1 The molecular basis of sensitization and pain
Annemarie Malfait, USA

13.30 INV2 Pain and consequences for SpA patients
Annelies Boonen, The Netherlands

SESSION 2: Spondyloarthritis in the post-genetics, pre-personalized medicine era
Chairs: John Reveille & Francesco Ciccia

14.00 INV3 Could genetics be useful for clinical practice?
Maxime Breban, France

14.25 INV4 Syndromes and rare disease, a toolkit for understanding spondyloarthritis
Corinne Miceli, France

14.50 INV5 Opportunities for early remission in spondyloarthritis: A long-lasting effect?
Philippe Carron, Belgium

15.15 Coffee Break and ePoster Viewing

Thursday 9 September

SESSION 3: Spondyloarthritis in the post-genetics, pre-personalized medicine era
Chairs: Georg Schett & Xenofon Baraliakos

15.45 INV6 Crystals as activator of immunity
Bart Lambrecht, Belgium

16.15 INV7 Neutrophils and NETs as orchestrators of chronic inflammatory disease
Martin Herrmann, Germany

Selected Oral Presentations I

16.45 O1 Comprehensive epigenomic profiling reveals disease-specific chromatin states in ankylosing spondylitis
Carla Cohen, UK

17.00 O2 Phenotypic, histologic and imagiologic characterization of transmembrane tumor necrosis factor transgenic mice
Elsa Vieira-Sousa, Portugal

17.15 O3 MHC haplotype controls development of IL-23 minicircle-induced murine spondyloarthritis
Joerg Ermann, USA

Keynote Lecture - The Ghent SpA Oration
Chair: Rik Lories

17.30 INV8 A journey of discovery through axial spondyloarthritis
Maxime Dougados, France

Friday 10 September
Session 4: Chasing the ghost: Disease modification in axSpA
Chairs: Martin Rudwaleit & Barbara Neerinckx

08.30 INV9 The translational rheumatologist’s view
Georg Schett, Germany

09.00 INV10 The absolutely correct way to assess Disease Modification in 2021
Robert Landewé, The Netherlands

09.30 INV11 Lessons learnt from studies of Disease Modification to optimally manage patients in the clinic
Denis Podubnyy, Germany

10.00 Coffee Break and ePoster Viewing

Selected Oral Presentations II
Chairs: Filip Van den Bosch & Robert Landewé

10.30 O4 The ASAS-OMERACT core domain set for axial spondyloarthritis
Victoria Navarro Compán, Spain

10.45 O5 Co-medication with a csDMARD is associated with improved outcomes of TNF inhibitors in patients with axial spondyloarthritis: Results from the EuroSpA collaboration
Michael Nissen, EuroSpA Research Collaboration, on behalf of DANBIO, Denmark

11.00 O6 Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis: Baseline and two-year follow-up data from the Be-GIANT cohort
Ann-Sophie De Craemer, Belgium

11.15 O7 Functional genomics of RUNX3 regulatory SNPs associated with ankylosing spondylitis
Matteo Vecellio, UK & Italy

11.30 O8 Th17 expansion is partially inhibited by IL-23, where poly functional Th17-derived cells are amplified by cellular stress in psoriatic arthritis
Carmel Stober, UK

11.45 O9 Gut-joint migratory T cells are cytokine competent and contribute to inflammation in the joint
Adam Lefferts, USA

12.00 Lunch

Session 5: Novel technologies and innovations in pathogenesis
Chairs: Maxime Breban & Désirée van der Heijde

13.30 INV12 New imaging tools in spondyloarthritis
Connie van der Laken, The Netherlands

13.55 NV13 The deep dive – Single cell sequencing
Martin Guilliams, Belgium

14.20 INV14 The data analyst: How to link clinical observations with new knowledge generation
Rachel Knevel, The Netherlands

Selected Oral Presentations III

14.45 O10 Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the ULTIMATE study
Maria-Antonietta D'Agostino, Italy

15.00 O11 Interleukin-23 inhibitors and their apparent ineffectiveness in treating axial spondyloarthritis: A systematic review with meta-analysis
Louise Vanhoutte, Belgium

15.15 O12 A first in disease phase 2a trial of granulocyte monocyte colony stimulating factor neutralisation for axial spondyloarthritis (NAMASTE study)
Hussein AL-Mossawi, UK

15.30 O13 Metabolomics profiling of serum for biomarker discovery to identify psoriatic arthritis and ankylosing spondylitis
Walter Maksymowych, Canada

15.45 O14 Dendritic cells influence T cell fate and pathogenicity in HLA-B27 transgenic rat model of spondyloarthritis
Simon Glatigny, France
Friday 10 September

16.00 Coffee Break and ePoster Viewing

Keynote Lecture – Basic Science
Chair: Dirk Elewaut

16.30 INV15 Regulatory and memory T cells in immune-mediated disease
Femke van Wijk, The Netherlands

Saturday 11 September

Session 6: Gut and SpA
Chairs: Filip Van den Bosch & Ann-Sophie De Craemer

08.30 INV16 Gut and SpA: New targets for treatment
Francesco Ciccia, Italy

08.55 INV17 The SpA Menu: Can diet be used as a treatment?
João Sabino, Belgium

09.20 INV18 Innate-like T cells in SpA: Friends or foes?
Koen Venken, Belgium

Selected Oral Presentations IV

09.45 O15 Factors associated with switching from one TNFi agent to another TNFi, or IL-17i agent in patients with ankylosing spondylitis
John Reveille, USA

10.00 O16 Correspondence between patient-reported flare and disease activity score variation in axial spondyloarthritis
Maxime Breban, France

10.15 O17 CHOP deficiency does not prevent gut inflammation in experimental spondyloarthritis
Fatemeh Navid, USA

10.30 O18 Novel use of specific drugs attenuates the pro-inflammatory cytokines IL-17A and IFN-gamma
Rajinder Singh Andev, UK

10.45 O19 Neutrophil-derived MIF is a critical driver and potential therapeutic target in spondyloarthritis
Akihiro Nakamura, Canada

11.00 Coffee Break and ePoster Viewing
Saturday 11 September

Session 7: New interdisciplinary perspectives for spondyloarthritis
Chairs: Maria-Antonietta D'Agostino & Philippe Carron

11.30 INV19 Emerging imaging techniques in spondyloarthritis: Dual-energy computed tomography and new MRI sequences
Lennart Jans, Belgium

11.55 INV20 Impact of comorbidities on clinical management
Ennio Lubrano, Italy

12.20 INV21 In silico medicine – Beyond the frontier
Liesbet Geris, Belgium

12.45 Closure of the Congress
Rik Lories, Congress President

P1 Voluntary wheel running model in mice to mechanically stimulate the enthesis of the Achilles tendon
Carole Bougault, France

P2 Elucidating the differentiation bias of naïve CD4+ T cells in HLA-B27 transgenic rat (B27-rat) model of spondyloarthritis (SpA)
Bilade Cherqaoui, France

P3 Long-term course of serum markers of bone turnover during 10 years of TNF-α inhibitors in patients with ankylosing spondylitis
Mark Siderius, The Netherlands

P4 GDF15 is not required for normal osteoclast function nor steady state and osteoporosis
Renée Van der Cruyssen, Belgium

P5 Predictors of ankylosing spondylitis activity during pregnancy
Olga Krichevskaya, Russia

P6 Disadvantages of using the BASDAI index to assess ankylosing spondylitis activity during pregnancy
Olga Krichevskaya, Russia

P7 Progression of radiographic sacroiliitis in patients with early axial spondyloarthritis over 3 years of follow-up
Daria Rumiantceva, Russia

P8 Radiological Progression of the hip joints lesions of the patients with early ankylosing spondylitis
Ekaterina Agafonova, Russia

P9 Treatment efficacy of non-steroidal anti-inflammatory drugs on X-ray progression of the hip joints lesions
Ekaterina Agafonova, Russia

P10 Correlation of radiological progression and MRI changes of the hip joints in patients with axial spondiloarthritis
Ekaterina Agafonova, Russia

P11 Maternal and neonatal pregnancy outcomes in ankylosing spondylitis
Olga Krichevskaya, Russia
Predictors of axial involvement in early psoriatic arthritis
Elena Gubar, Russia

Association of axial involvement in psoriatic arthritis with worse disease outcomes
Elena Gubar, Russia

Similar clinical responses, safety and treatment persistence with ustekinumab in younger vs older patients with psoriatic arthritis at 12 months in the real-world PsABio study
Elke Theander, Sweden

Ustekinumab and TNFi safety data and cardiovascular events in psoriatic arthritis: Results from the real-world PsABio study
Elke Theander, Sweden

Quality of life and impact of psoriatic arthritis
Adela Gallego Flores, Sweden

Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey (ATTENTUS-axSpA)
Uta Kiltz, Germany

Self-monitoring of disease activity by smartphone app in patients with axial spondyloarthritis
Uta Kiltz, Germany

Impact of COVID-19 pandemic in overall health and functioning in patients with axial spondyloarthritis: Results from the REUMAVID Study (Phase 1)
Diego Benavent, Spain

Portrait of a patient with axial spondyloarthritis: Results of an online survey of 233 EMAS patients of the Russian Federation
Svetlana Lapshina, Russia

Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis
Kwi Young Kang, South Korea

Association between individual and country-level socioeconomic factors and health outcomes in axial and peripheral spondyloarthritis: Analysis of the ASAS perSpA study
Dafne Capelusnik, Argentina

Peripheral arthritis and higher disease activity lead to more functional impairment in axial Spondyloarthritis: Longitudinal analysis from ESPAXIA
Dafne Capelusnik, Argentina

Performance of standardized scores for disease assessment and pain in patients with spondyloarthritis and fibromyalgia
Xenophon Baraliakos, Germany

ASDAS-CRP remission and long-term functional outcomes: A real-life ankylosing spondylitis (AS) cohort study
Charles Kohem, Brazil

5-years follow-up analysis of PsA activity in patients treated according to Treat-to-Target (T2T) strategy at the early stage
Polina Tremaskina, Russia

Radiographic enthesal lesions at pelvic region are associated with longer disease duration, higher BMI and more severe spinal and hip radiographic damage in patients with ankylosing spondylitis
Fréke Wink, The Netherlands

Evaluation of the Framingham Risk Score in patients with psoriatic disease in a mixed population
Sueli Carneiro, Brazil

Patients’ perspectives on patient education in axial spondyloarthritis: A qualitative study
Yvonne van der Kraan, The Netherlands

Impact of diagnostic delay on quality-of-life measures in axial spondyloarthritis
Zoya Qaiyum, Canada

Radiographic progression of sacroiliac joints in early axial spondyloarthritis does not depend on disease activity and patient gender
Daria Rumiantceva, Russia

Remission in patients with early axial spondyloarthritis from the CORSAR cohort during 3 years of follow-up
Daria Rumiantceva, Russia
P33 Improvement in quality of life with Secukinumab treatment in Ankylosing Spondylitis - Data from the Rheumatic Diseases Portuguese Registry (Reuma.pt) 
Helena Santos, Portugal

P34 Comparison of health-related quality of life in spondyloarthritis and low back pain patients – results from a population-based study 
Helena Santos, Portugal

P35 The impact of socioeconomic status on clinical parameters in female PsA patients 
Ibrahim Tekeoğlu, Turkey

P36 Assessment of the impact of the COVID-19 Pandemic from the perspective of patients with rheumatic diseases in Europe: Results from REUMAVID (First phase) 
Victoria Navarro-Compán, Spain

P37 Determinants of poor wellbeing during the COVID-19 pandemic in patients with rheumatic diseases in Europe: Results from REUMAVID (First phase) 
Victoria Navarro-Compán, Spain

P38 Gender differences from the patient perspective on the impact of the COVID-19 pandemic in patients with rheumatic diseases in Europe: Results from REUMAVID (First phase) 
Victoria Navarro-Compán, Spain

P39 Family history of rheumatic diseases in patients with psoriatic arthritis: A multi-institutional cross-sectional study 
Kemal Nas, Turkey

P40 Frequency of axial spondyloarthritis diagnosis among patients with chronic low back pain seen by rheumatologists in Kinshasa, Democratic Republic of the Congo 
Pierrot Lebughe, Congo

P41 Uveitis occurrence in early inflammatory back pain - Five years data from the prospective French nationwide cohort DESIR 
Daniel Wendling, France

P42 One in twenty inflammatory bowel disease patients with incidental computer-tomographic evident sacroiliitis have undiagnosed axial spondyloarthritis 
Chong Seng Edwin Lim, UK

P43 Experience to 6 years in the multidisciplinary consultation of psoriasis arthropathy in a reference hospital 
Calvo Itziar, Spain

P44 Being overweight is associated with not reaching low disease activity in women but not men with psoriatic arthritis 
Michelle Mulder, The Netherlands

P45 Extra-articular and extra-spinal manifestations in patients with early axial spondyloarthritis from the CORSAR cohort during 3 years of follow-up, managed according to the T2T strategy 
Daria Rumiantceva, Russia

P46 Relationship between biomarkers and indices of ankylosing spondylitis activity 
Daria Rumiantceva, Russia

P47 Vaspin in subclinical atherosclerosis and cardiovascular risk in axial spondyloarthritis 
Fernanda Genre Romero, Spain

P48 Comparison of the distribution by department of the prevalence of spondyloarthritis and inflammatory bowel diseases in metropolitan France and their evolution between 2008 and 2018 
Daniel Wendling, France

P49 Monocentric retrospective descriptive study of a hospital population of spondyloarthritis (SPA) with a history of cancer 
Daniel Wendling, France

P50 Sex differences in correlation of spinal mobility and functional impairment in axial spondyloarthropathy 
Sinead Maguire, Ireland

P51 Negative impact of unemployment in axial spondyloarthritis: results from the ankylosing spondylitis registry of Ireland 
Sinead Maguire, Ireland

P52 Health related quality of life in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: Results from a questionnaire study 
Anton Landgren, Sweden
P53 Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention
Anton Landgren, Sweden

P54 Prevalence of undiagnosed axial spondyloarthritis among secondary care patients with inflammatory bowel disease
Chong Seng Edwin Lim, UK

P55 Age at onset in axial spondyloarthritis around the world: Data from the international ASAS-PerSpA study
Anne Boel, The Netherlands

P56 Geographical prevalence of a family history in patients with axial spondyloarthritis and its association with HLA-B27: Data from the worldwide ASAS-perSpA study
Miranda van Lunteren, The Netherlands

P57 Effectiveness of repeating the tuberculin skin test in patients with chronic inflammatory arthropathies on TNFα inhibitors exposition: A 10-year retrospective cohort
Vanessa Magalhães, Brazil

P58 Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study
Diego Benavent, Spain

P59 Serum biomarkers before and after a six months structured weight loss intervention in patients with psoriatic arthritis and obesity compared with controls
Linda Torres, Sweden

P60 Extracellular matrix protein turnover markers are associated with axSpA – A comparison with control subjects with or without pelvic, buttoc or back pain
Helena Port, Denmark

P61 Two-year diagnostic consistency in patients with chronic back pain suspected of axial spondyloarthritis: Data from the SPACE cohort
Anne Boel, The Netherlands

P62 Comparison of work outcomes between chronic back pain patients with and without a diagnosis of axial spondyloarthritis: Data from the SPACE cohort
Anne Boel, The Netherlands

P63 Predictors of biologic therapy and syndesmophyte formation in patients with non-radiographic axial spondyloarthritis
Carla Saad, Brazil

P64 Quality of life in chronic back pain patients, a 2-year comparison between patients with and without a diagnosis of axial spondyloarthritis: Data from the SPACE cohort
Anne Boel, The Netherlands

P65 External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three phase-3 RCTs
Augusta Ortolan, Italy

P66 Altered splicing in leukocytes from patients with axial spondyloarthritis: Clinical involvement
Chary Lopez-Pedrera, Spain

P67 Can serum calprotectin be used as an alternative biomarker of inflammation in spondyloarthritis?
Ksenia Sakharova, Russia

P68 Association between individual and country-level socioeconomic factors and work participation in peripheral and axial spondyloarthritis
Sizheng Zhao, UK

P69 Online questionnaire in axSpA diagnostics
Ekaterina Gaydukova, Russia

P70 Spondyloarthritis mortality related to COVID-19 is similar to rheumatoid arthritis and systemic lupus erythematosus – Data from the ReumaCoV-Brazil Registry
Marcelo Pinheiro, Brazil

P71 Performance of three referral algorithms for diagnosing axial spondyloarthritis
Walter Maksymowych, Canada

P72 Cluster of differentiation 14 (CD14) and Lipopolysaccharide-binding protein (LBP) in psoriatic arthritis and spondyloarthritis
Isabella W. Paulsen, Denmark
Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol: Pregnancy outcomes and confounders
Megan Clowse, UK

Transcriptome analysis of monocyte-derived dendritic cells from spondyloarthritis (SpA) patients reveals a major impact of B27 on gene expression
Audrey Hulot, France

Central sensitization has major impact on quality of life in patients with axial spondyloarthritis
Stan Kieskamp, The Netherlands

The prevalence of inflammatory back pain and HLA-B27 in a large population-based cohort in the Netherlands
Stan Kieskamp, The Netherlands

The diagnostic utility of serum interleukin 22 in patients with suspected axial spondyloarthritis
Gleb Slobodin, Israel

Diagnosing axial SpA by multidisciplinary team conference in a cohort of patients with disease features according to the ASAS criteria
Clara Mistegård, Denmark

HLA-B27 gene did not protect against COVID-19 in patients with axial spondyloarthritis – ReumaCoV-Brasil Registry
Guilherme Mota, Brazil

Characteristics of the patients with ankylosing spondylitis achieved axial spondyloarthritis remission due to Russian SpA group definition
Inna Gaydukova, Russia

Muscle dysfunction in axial Spondylarthitis - The MyoSpA study
Agna Neto, Portugal

Determinants of health related quality of life in rheumatoid arthritis and spondyloarthritis: How do they interact from a hierarchical perspective?
Pedro Machado, UK

Identifying trajectories of radiographic spinal disease in ankylosing spondylitis
Mark Hwang, USA

Serum IgG-undergalactosylation reflects cumulative exposure to systemic inflammation in spondyloarthritis patients
Ann-Sophie De Craemer, Belgium

Spondyloarthritis and its subtypes prevalence in three European countries
Mirjana Zlatković-Švenda, Serbia

Does the level of matrix metalloproteinase-3 correlate with inflammation in ankylosing spondylitis?
Ksenia sakharova, Russia

HLA-B alleles in a cohort of patients with inflammatory back pain
Alexandra Maria Burlui, Romania

Molecular profiling of radiographic axial spondyloarthritis patients reveals an association between innate and adaptive cell populations and therapeutic response to Adalimumab
Daniel Sobral, Portugal

Role of HLA-B27 carrier ship in peripheral spondyloarthritis: Data from ASAS perSpA Study
Marta Arévalo, Spain

Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacro-iliac joints of healthy subjects and patients with spondyloarthritis
Daniel Wendling, France

Predictive capacity for vertebral fracture of the Trabecular Bone Score in patients with axial spondyloarthritis
Elia Valls Pascual, Spain

Description of sacroiliac CT findings in patients with ankylosing spondylitis aged over 50 years: Preliminary results of the CASIAGE study
Daniel Wendling, France

Limitations of the use of magnetic resonance imaging in evaluation of the biological treatment effectiveness in late stage of axial spondyloarthritis
Pavel Shesternya, Russia
P94 Could the Total Spine MRI be useful for decision-making in patients with ankylosis spondylitis? Data from a 2-Year prospective study
Louise Bendahan, Brazil

P95 In radiographic axial spondyloarthritis, bridging syndesmophytes increase risk of facet joint ankylosis on the same vertebral level while facet joint ankylosis does not increase risk of same level syndesmophytes
Rosalinde Stal, The Netherlands

P96 MRI vertebral corner inflammation and fat deposition are associated with whole spine low dose CT detected syndesmophytes
Rosalinde Stal, The Netherlands

P97 The influence of age on the prevalence of inflammatory and post-inflammatory MRI lesions in the SIJ of patients with and without axSpA
Xenofon Baraliakos, Germany

P98 Adalimumab-induced severe recurrent face furunculosis in a young patient with active ankylosing spondylitis - A clinical case
Ksenia Sakharova, Russia

P99 Ultrasound (US) signs of inflammation and achieving minimal disease activity in Psoriatic Arthritis (PsA) patients
Olga Alekseeva, Russia

P100 Diagnostic utility of IBP criteria in an inception cohort of patients with psoriasis, iritis, or colitis presenting with undiagnosed back pain
Walter Maksymowycz, Canada

P101 Does imaging of the sacroiliac joint differ in patients presenting with undiagnosed back pain and psoriasis, acute anterior uveitis, and colitis: An inception cohort study
Walter Maksymowycz, Canada

P102 Structural damage in axSpA: Is there a preferred way to assess progression?
Xenofon Baraliakos, Germany

P103 Radiographic sacroilitis progression up to 6 years of follow-up in patients with non-radiographic axial spondyloarthritis
Stan Kieskamp, The Netherlands

P104 Data-driven definitions based on inflammatory lesions for a positive MRI of the spine consistent with axial spondyloarthritis
Walter Maksymowycz, Canada

P105 Consensus definitions for MRI Lesions in the spine of patients with axial spondyloarthritis: First analysis from the assessments in SpondyloArthritis International Society Classification Cohort
Walter Maksymowycz, Canada

P106 Scoring MRI structural lesions in sacroiliac joints of patients with axial spondyloarthritis: How many slices are optimal?
Walter Maksymowycz, Canada

P107 Enrichment of RORyt+ Innate-like T Cells in joint and gut samples from spondyloarthritis Patients
Céline Mortier, Belgium

P108 Proinflammatory osteopontin and CCL2 are spontaneously produced by psoriatic arthritis synovial myeloid cells
Nicole Yager, UK

P109 Immunoglobulin G antibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts
Pieter Ruytinx, Belgium

P110 Screening for immunoglobulin A antibody reactivity in early axial spondyloarthritis identifies novel peptide targets
Pieter Ruytinx, Belgium

P111 Overexpression of TLR-2 and TLR-4 in gut-homing Tγδ cells of axSpA patients
José Pablo Romero-López, Mexico

P112 CD27−CD38lowCD21low B-cells are increased in ankylosing spondylitis
Rick Wilbrink, The Netherlands

P113 High dimensional immune profiling of CD8+ T cell subsets and immune checkpoints implicate a dysregulation of cytotoxic T lymphocytes (CTLs) in ankylosing spondylitis
Michael Tang, Canada

P114 Frequency and characteristics of inflammatory bowel disease in spondyloarthritis with biological therapy
Calvo Itziar, Spain
Intestinal permeability in spondyloarthritis: A systematic review of the literature
Daniel Wendling, France

Association of gut dysbiosis with radiographic and enthesitis involvement and disease activity in axial spondyloarthritis - Data from CASTRO Registry
Ignacio Gómez-García, Spain

Study of microbiota contributions to gut & joint disease using transgenic germ-free mouse technology
Lars Vereecke, Belgium

New biologic and targeted synthetic DMARDs for the treatment of PsA - How are they positioned in clinical practice?
Patrícia Martins, Portugal

Study of patients treated with secukinunmab in the same hospital the two years
Calvo Itziar, Spain

Collagen turnover markers associate with active psoriatic arthritis and decrease with guselkumab treatment
Kristen Sweet, USA

Integrated safety results of two phase-3 trials of guselkumab in patients with psoriatic arthritis through the placebo-controlled periods
Shelly Kafka, USA

Guselkumab provides domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis
Wim Noël, Belgium

Efficacy of guselkumab on axial-related endpoints in patients with active psoriatic arthritis with imaging-confirmed sacroiliitis
May Shawi, USA

Low disease thresholds up to three years in ixekizumab-treated patients with psoriatic arthritis in SPIRIT-P1 and SPIRIT-P2
Laura Coates, UK

Secukinumab real world evidence: A multicentric experience
Garcia Martos Álvaro, Spain

Reversion of active MRI sacroiliitis symptoms after tofacitinib treatment in psoriatic arthritis patients
Elena Gubar, Russia

The (cost-)effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis
Manja A.T. van Wissen, The Netherlands

Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with ankylosing spondylitis: Multicenter, randomised, double-blind, Phase IV ASTRUM-trial
Uta Kiltz, Germany

Long-term outcomes with filgotinib, an oral preferential Janus kinase 1 inhibitor: 100-week data from an open-label extension (OLE) study in patients with PsA
Laura Coates, UK

Impact of filgotinib on structural lesions in the sacroiliac joints at 12 weeks in patients with active ankylosing spondylitis: Correlation with clinical endpoints
Walter Maksymowycz, Canada

Effects of filgotinib on spinal lesions in patients with ankylosing spondylitis: magnetic resonance imaging data from the placebo-controlled, double-blind, randomized TORTUGA trial
Walter Maksymowycz, Canada

Targeted serum proteomic analysis following upadacitinib treatment in ankylosing spondylitis shows robust suppression of innate and adaptive immune pathways with tissue repair modulation
Dennis McGonagle, UK

Bimekizumab long-term safety in patients with ankylosing spondylitis and psoriatic arthritis: 3-year results from BE AGILE and BE ACTIVE
Denis Poddubnyy, Germany

Effects of ixekizumab treatment on structural changes in the sacroiliac joints based on MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis
Walter Maksymowycz, Canada
P135  Evaluation of spinal radiographic progression in patients with radiographic axial spondyloarthritis receiving ixekizumab therapy over 2 years  
Désirée van der Heijde, The Netherlands

P136  Patients with radiographic axSpA who progressed from ASAS20 at week 16 to ASAS40 at week 52: Results from COAST-W  
Xenofon Baraliakos, Germany

P137  Extra-musculoskeletal Manifestations driving the therapeutic decision in patients with spondyloarthritis: A 12-month follow-up study  
Marcelo Pinheiro, Brazil

P138  Treat-to-target in axial spondyloarthritis: An observational study in daily practice  
Esther Beckers, The Netherlands

P139  Subsets of Th- and cytotoxic T-cells in patients with axial spondyloarthritis treated with biologic agents  
Pavel Shesternya, Russia

P140  Tocilizumab in HLA-B27 positive, severe peripheral Spondyloarthritis  
Nikolaos Kougkas, Greece

P141  Inhibition of interleukin 17 reduces myocardial dysfunction in patients with ankylosing spondylitis  
Svetlana Lapshina, Russia

P142  Ultrasound-guided injections of sacroiliac joint – An old and a new treatment!  
Carolina Mazeda, Portugal

P143  Lower levels of physical activity are associated with evasive coping, higher BMI and worse outcome in patients with AxsPA  
Marlies Carbo, The Netherlands

P144  Effectiveness and treatment retention of TNF-inhibitors when used as monotherapy versus co-medication with csDMARDs in 15332 patients with psoriatic arthritis - Data from the EuroSpA collaboration  
Michael Nissen, Switzerland

P145  Coxitis in ankylosing spondylitis (AS) treated with TNF-alpha inhibitor golimumab: Results of a 24-months observation (GO-COX study)  
Vladimir Achikyan, Russia

P146  Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement  
Atul Deodhar, USA

P147  Effect of upadacitinib on reducing pain in patients with active ankylosing spondylitis and inadequate response to NSAIDs  
Atul Deodhar, USA

P148  Above-label dosing and costs in Ankylosing Spondylitis (AS) patients using certolizumab pegol or secukinumab in US  
Anna Sheahan, UK

P149  Physiotherapy WORKs: RCT on the (cost-)effectiveness of a physical therapist-led, work-oriented intervention in people with axial spondyloarthritis and rheumatoid arthritis  
Nienke Bakker, The Netherlands

P150  Do the indications for the administration of interleukin 17 or TNF inhibitors in spondyloarthritis differ in real clinical practice? Experience of a specialized rheumatology hospital  
Erdes Shandor, Russia

P151  Effectiveness and safety of combined biological therapy in patients with spondyloarthritis  
Cristina Valero, Spain

P152  The TNF-NF-κB-DKK1 axis promoted mineralization in the enthesis of ankylosing spondylitis  
Sungsin Jo, South Korea

P153  Recruitment for a physiotherapy (cost-)effectiveness study in people with axial spondyloarthritis during the COVID-19 pandemic  
Manja A.T. van Wissen, The Netherlands

P154  Nonsteroidal anti-inflammatory drugs intake load and renal function in patients with spondylarthritis: An 18-year follow-up study  
Victoria Carneiro Dal Moro, Brazil

P155  Pharmacological treatment of enthesitis - a systematic review on the efficacy of the available options  
Ana Rita Pinheiro Torres da Silva, Portugal
P156  Treatment with Tofacitinib in refractory psoriatic arthritis - Multicenter study of 87 patients in clinical practice  
Eva Galindez Agirregoikoa, Spain

P157  Clinical evaluation of patients with axial spondyloarthritis under treatment with NSAIDs and physiotherapy in Kinshasa, Democratic Republic of the Congo  
Pierrot Lebughe, Congo

P158  Efficacy of guselkumab across BASDAI components in treating axial-related symptoms of psoriatic arthritis: Results from two phase-3, randomized, placebo-controlled studies  
Frank Behrens, Germany

P159  Effectiveness of a biologic tapering protocol for axial spondyloarthritis and psoriatic arthritis (TaPSpA)  
Pedro Manuel Avila-Ribeiro, Portugal

P160  Predictive factors of secukinumab persistence in patients with psoriatic arthritis - Data from the Rheumatic Diseases Portuguese Registry (Reuma.pt)  
José Costa, Portugal

P161  Long-term experience of biological therapy in different kinds of juvenile spondyloarthritis  
Irina Nikishina, Russia

P162  Adalimumab treatment in a patient with PASS syndrome  
Danil Dibrov, Russia

P163  Multidisciplinary working in the management of axial and peripheral spondyloarthritis  
Tania Gudu, UK

P164  The experience of a rheumatologist work with «ASpine» technology for monitoring the condition of patients with axial spondyloarthritis in the COVID-19 pandemic  
Daria Rumiantceva, Russia

P165  Disease activity, functional impairment and work disability in an ankylosing spondylitis cohort  
Alexandra Maria Burlui, Romania

P166  Body mass index may be linked to functional impairment in men with ankylosing spondylitis  
Alexandra Maria Burlui, Romania

P167  Work disability in women with ankylosing spondylitis and rheumatoid arthritis: A single-center observational study  
Alexandra Maria Burlui, Romania

P168  Signs of central sensitization in patients with ankylosing spondylitis  
Ekaterina Filatova, Russia

P169  Radiographic versus non-radiographic axial spondyloarthritis: Comparison of daily self-reported flare experience  
Rosemarie Barnett, UK

P170  The mSQUASH; a valid, reliable and responsive questionnaire for daily physical activity in patients with axial spondyloarthritis  
Marlies Carbo, The Netherlands

P171  Clinical characteristics of COVID-19 in patients with ankylosing spondylitis: The Republic of Tatarstan experience  
Svetlana Lapshina, Russia

P172  Sex-specific challenges in patients with psoriatic arthritis (PsA): Preliminary results from a systematic literature review (SLR)  
Laura Coates, UK

P173  Impact of skin severity on psoriatic arthritis activity, quality of life (QoL) and work productivity  
Lyubov Vorobyova, Russia

P174  Risk factors associated with unfavorable COVID-19 in spondyloarthritis patients – Data from the ReumaCoV-Brazil Registry  
Claudia Marques, Brazil

P175  Distribution of comorbidities in spondyloarthritis with regard to the phenotype and the presence of psoriasis: Data from the ASAS-COMOSPA study  
María Ángeles Puche Larrubia, Spain

P176  Blockade of Interleukin Seventeen (IL-17A) in Hospitalized COVID-19 patients – the BISHOP study  
Gustavo Resende, Brazil
P177  Unexpected clinical findings as an evidence of the relation of fibrodysplasia ossificans progressiva to axial spondyloarthritis
Irina Nikishina, Russia

P178  Evaluation of cardiometabolic risk factors in patients with ankylosing spondylitis
Ayfer Altaş, Turkey

P179  The problems of magnetic resonance tomography diagnostics of patients with axial spondyloarthritis
Elizaveta Vasilenko, Russia

P180  The validity of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) in a Russian cohort of patients
Shandor Erdes, Russia

P181  Clinical features and outcomes of COVID-19 patients with chronic inflammatory rheumatic disease: A retrospective case-control study
Kemal Nas, Turkey
---

**Tremfya®**

**LASTING, CONSISTENT RELIEF**

**FOR A LIFE THAT’S NON-STOP**

**IN PSORIATIC ARTHRITIS AND PSORIASIS**

---

Psoriatic arthritis: Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug (DMARD) therapy. Plaque psoriasis: Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

---

Zeer vaak:

- Vaak (≥1/100, <1/10)
- Zelden (≥1/1000, <1/100)
- Zelden (≥1/10.000, <1/1000)
- Zeer zelden (<1/10.000)
- Niet bekend (kan met de beschikbare gegevens niet worden bepaald).

---

**Dosering en wijze van toediening:**

- **Adultes:** De aanbevolen dosis van Tremfya is 100 mg via subcutane injectie in week 0 en week 4, gevolgd door een onderhoudsdosis eenmaal per 8 weken. Voor patiënten die op basis van klinisch oordeel een hoog risico hebben voor artralgie, is een dosis van 100 mg bijwerking wordt verhoogd (zoals hierboven) gemeld bij 12,9% van de patiënten in de q4w-groep en 9,1% van de patiënten in de q8w-groep. Bijwerkingen zoals hypertransaminasemie vaker gemeld in de met Tremfya behandelde groepen (8,6% in de q4w-groep en 8,3% in de q8w-groep) werden als zodanig niet verhoogd. Bijwerkingen zoals neutrofilleucopenie werden bij 12,9% van de patiënten in de q4w-groep en 9,1% van de patiënten in de q8w-groep gevonden, maar waren niet verhoogd.

---

**Immunogeniciteit:**

De immunogeniciteit van Tremfya werd geëvalueerd met behulp van een gevoelige, voor het geneesmiddel tolereante methode op de basis van de immuunrespons bij patiënten met artralgie. De bijwerkingen erytheem op de injectieplaats en pijn op de injectieplaats waren de meest gemelde bijwerkingen. Bijwerkingen die ernstig waren, leidden niet tot het stoppen van Tremfya. In twee klinische studies bij psoriasis kwamen t/m week 48 bij 3,0% van de injecties met Tremfya...
Improving the lives of axSpA patients

Our trials answer key questions around the understanding and management of patients across the axSpA disease spectrum.

Is certolizumab pegol efficacious across nr-axSpA and r-axSpA/AS?

Is nr-axSpA self-limiting with the potential for remission and what is the optimal treatment?

Can clinical remission in early axSpA be maintained while reducing the certolizumab pegol dose?

Is certolizumab pegol effective in reducing flares of acute anterior uveitis* in axSpA patients? (both r-axSpA/AS and nr-axSpA)

*CZP is not licensed for the treatment of uveitis in the European Union.

Our trials answer key questions around the understanding and management of patients across the axSpA disease spectrum.

Is nr-axSpA self-limiting with the potential for remission and what is the optimal treatment?

Can clinical remission in early axSpA be maintained while reducing the certolizumab pegol dose?

Is certolizumab pegol effective in reducing flares of acute anterior uveitis* in axSpA patients? (both r-axSpA/AS and nr-axSpA)

*CZP is not licensed for the treatment of uveitis in the European Union.

© UCB Biopharma SRL, 2021. All rights reserved.

GL-N-CZ-axSpA-2100067

Date of preparation: August 2021
Platinum Sponsors

abbvie  Lilly  NOVARTIS  Pfizer  ucb

Gold Sponsor

Janssen

Silver Sponsors

AMGEN  Galápagos